Vir Biotechnology and GSK provide update on NIH-sponsored ACTIV-3 trial evaluating VIR-7831 in hospitalised adults with COVID-19

The DSMB has recommended that the VIR-7831 arm of the trial be closed to enrolment while the data mature.